CPT Code 87661: Trichomonas vaginalis NAAT billing guide

Key takeaways

CPT Code 87661 covers nucleic acid amplification testing (NAAT) for Trichomonas vaginalis, the most common curable STI in the United States.

Medicare pays $35.09 for 87661 under the Clinical Laboratory Fee Schedule, the same national rate as 87481, 87491 and 87591.

Pair 87661 with ICD-10 code A59.01, A59.09, or Z11.3 to establish medical necessity, then check your MAC’s LCD.

The CPT descriptor carries no gender restriction, so a female-only edit still live in your billing system is a local configuration problem.

Pabau connects to Claim.MD for real-time eligibility checks, 837P claim submission, and ERA/835 remittance reconciliation.

CPT Code 87661 is the billable code for infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique. It covers NAAT testing for trichomoniasis on a vaginal swab, a cervical swab, or urine. Medicare prices it under the Clinical Laboratory Fee Schedule, not the Physician Fee Schedule.

Trichomoniasis is the most prevalent curable sexually transmitted infection in the United States. The CDC estimates approximately 2.6 million infections each year. NAAT has replaced wet prep and culture as the diagnostic standard, because it finds infections the older methods miss.

Three failure points account for most denials on this code, and each one is fixable before the claim goes out:

• An ICD-10 pairing the payer’s policy does not cover.
• A bundling collision with 87491 or 87591 in the same NAAT panel.
• A female-only gender edit still active in the billing system.

What CPT Code 87661 covers

CPT Code 87661 sits in the Infectious Agent Detection by Nucleic Acid (DNA or RNA) section of the CPT codebook. The American Medical Association maintains that code set. The full official descriptor reads: Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique.

The amplified probe technique language is the operative part of that descriptor. It separates 87661 from non-amplified probe detection, and it confirms that NAAT methodology is required to bill the code. A lab running a rapid antigen test or a wet prep cannot report 87661.

Why Trichomonas vaginalis requires NAAT testing

Trichomonas vaginalis is a protozoan parasite responsible for trichomoniasis. Up to 70% of infections are asymptomatic, so clinical presentation alone is an unreliable screen. Wet preparation microscopy, the older standard, has sensitivity of only 51-65% according to CDC STI treatment guidelines. NAAT reaches 95-100% sensitivity on the same specimen types.

The clinical case follows from that difference. Missed diagnoses perpetuate transmission and raise the risk of HIV acquisition. In pregnant patients, untreated infection is associated with preterm delivery. Aetna and Anthem both cover 87661 for symptomatic patients and defined screening populations, because the sensitivity gain justifies the higher cost.

• Sensitivity advantage: NAAT detects T. vaginalis in 95-100% of positive samples, against 51-65% for wet prep
• Specimen flexibility: Self-collected vaginal swabs and urine specimens are FDA-cleared for NAAT, so many patients need no pelvic exam
• Asymptomatic screening: The sensitivity of NAAT makes it the only practical option for screening asymptomatic high-risk populations
• Guideline support: CDC STI treatment guidelines recommend NAAT as the preferred diagnostic method over wet prep and culture

Medicare reimbursement for CPT Code 87661

CPT Code 87661 is reimbursed under the Medicare Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. Laboratory codes carry a single national rate, with no facility or non-facility split. CMS updates the schedule annually, effective each January 1.

The national CLFS rate for CPT Code 87661 is $35.09, and that figure has held since 2021. Confirm it against the current CMS clinical laboratory fee schedule files before you bill. Commercial rates vary widely from that benchmark.

The rate is also identical across the NAAT analytes a lab typically runs together, which changes how you should think about panel design.

The claim itself should carry the ordering provider’s NPI, the specimen type collected, and the applicable ICD-10 diagnosis code. Once the payer processes it, you receive an electronic remittance advice (ERA/835) with the payment or denial reason codes. Track those codes for NAAT-specific patterns rather than reading them claim by claim.

Reimbursement rates by payer

Commercial rates for CPT Code 87661 vary by payer and contract. The table below reflects the published position of each payer, and individual contract terms override it.

ICD-10 codes that establish medical necessity

Selecting the right ICD-10 diagnosis code is the single most effective way to prevent automatic denials on CPT Code 87661. The payer uses that code to judge medical necessity, and the covered list varies by payer and by local coverage determination (LCD). Full descriptors and coding notes for the diagnoses below sit in our ICD-10-CM codes reference.

Use the most specific code the documentation supports. A59.01 is preferred over A59.9 when the patient is symptomatic and the anatomical site is recorded. The CrossCoder CPT-to-ICD-10 crosswalk helps confirm which diagnosis codes your MAC’s LCD lists as covered for 87661. Check that the list is current, since LCDs are revised periodically and no single covered list applies across every Medicare Administrative Contractor.

Documentation a clean claim needs

Clean claims for CPT Code 87661 share a consistent set of documentation elements. Miss one and you are into denial management in healthcare, which typically adds three to four weeks before the money arrives.

1. Ordering provider NPI: A licensed provider must order the test, and that provider’s NPI appears on the claim separately from the rendering lab’s NPI.
2. Specimen type documentation: Record the specimen source in the medical record. Some payers apply coverage restrictions by specimen type.
3. Medical necessity documentation: The note has to support the ICD-10 code selected. For A59.01, record the symptoms. For Z11.3, record the risk factor that triggered the screen.
4. Date of service: Use the collection date, not the result date. A mismatch between the requisition and the claim is a common edit trigger.
5. Insurance eligibility verification: Confirm the plan covers NAAT testing before ordering, so a plan-specific exclusion surfaces before the specimen is collected.
6. Prior authorization: Anthem and some commercial plans require prior authorization for NAAT STI testing in defined populations. Check before ordering.

Submitting through a clearinghouse that validates the claim against payer edits before transmission catches errors while they are still cheap to fix. Practice management software like Pabau connects to Claim.MD, a US clearinghouse, for real-time eligibility checks and 837P claim submission. A claim that goes out correct on the first attempt avoids the rework cycle entirely.

Why some systems still reject 87661 for male patients

CPT Code 87661 carries no gender restriction in its descriptor. Any female-only edit that rejects a male patient is a billing-system rule, not a CPT rule. It survives from the code’s historical association with vaginal specimens. T. vaginalis infects male patients too, and urine NAAT from a male patient is an FDA-cleared specimen type.

The MDIN update cited in some coding write-ups is not a national Medicare policy. It traces to a 2014 Indiana Health Coverage Programs bulletin. The state Medicaid billing system had applied a gender edit to this code in error, and the bulletin corrected it. Treat that as a state-level fix, not a CMS instruction.

The practical action is to audit your practice management or lab information system and confirm no gender edit is active on 87661. A claim for a male patient will fail a front-end edit and never reach the payer. If male-patient claims still reject on gender, check your own configuration first, then your MAC’s front-end edits.

Bundling rules and NCCI edits

CPT Code 87661 is frequently ordered alongside 87491 for Chlamydia trachomatis and 87591 for Neisseria gonorrhoeae as a standard STI panel. Each is separately reportable with its own National Correct Coding Initiative (NCCI) edit status. As a general rule the three may be billed together on the same specimen from the same encounter, because they detect distinct pathogens.

NCCI bundling edits can change quarterly, so verify the current tables before adding a new analyte to a panel. Key bundling considerations for CPT Code 87661:

• 87661 + 87491: Separately reportable when distinct pathogens are tested. Confirm no edit exists in the current quarterly tables
• 87661 + 87591: The same rule applies, and this is the pairing most often billed with 87661
• 87661 + 87801: 87801 is a multi-analyte NAAT panel code. Billing 87661 alongside it when the panel already detects T. vaginalis may trigger a bundling denial. Check the analyte list of the specific 87801 panel before reporting both.
• Modifier -59: Where two codes would normally bundle but the service is genuinely distinct, append -59 or the applicable X-modifier. Document the clinical justification.

Related CPT codes in the NAAT STI panel

Knowing the wider family of NAAT STI codes helps with panel design and with avoiding unintentional bundling errors. The table below covers the codes most often billed alongside or instead of CPT Code 87661.

The AAPC Codify CPT lookup carries the full descriptions and current crosswalk data for each of these NAAT codes. When you bill a panel drawn from this family, check each pair against the current NCCI edit tables first.

Payer coverage policies, from Medicare to BCBS

Coverage for CPT Code 87661 is not automatic. Each major payer sets its own medical necessity criteria, and the claim documentation has to support them. Aetna, Anthem and Medicare broadly agree on symptomatic patients, then diverge sharply on asymptomatic screening.

Asymptomatic screening is the most variable area. Some Medicare MACs cover T. vaginalis NAAT screening for pregnant patients and HIV-positive individuals under specific LCDs. Commercial plans differ widely. When you order 87661 for asymptomatic screening, document the specific risk factor or guideline behind the test, rather than leaning on Z11.3 alone.

How Pabau handles NAAT panel claims end to end

Denials on this code start upstream of the claim. The wrong gender flag, a missing diagnosis code, or a specimen type nobody recorded all originate in the clinical record. They then travel into billing untouched, and the biller finds out three weeks later.

Pabau keeps the order, the specimen detail, the diagnosis code and the claim in one patient record. A biller working an 87661 rejection reads the requisition and the note in the same place. Nobody reconciles a lab system against a separate billing platform. For a service running STI panels at volume, that removes the handoff where supporting detail usually goes missing.

Claims leave through Claim.MD, the US clearinghouse Pabau integrates with. That covers real-time eligibility verification before the specimen is collected, 837P claim submission, and ERA/835 remittance reconciliation once the payer responds. Our claims management software keeps that loop inside the system that already holds the patient record.

Fewer rejected claims on NAAT panels

Pabau connects to Claim.MD for real-time eligibility checks, 837P claim submission, and ERA/835 remittance reconciliation. See how the billing loop runs from specimen collection through payment posting.

Book a demo

Conclusion

CPT Code 87661 rewards configuration more than effort. The rate is fixed at $35.09, the covered diagnosis list is short, and the bundling logic rarely shifts mid-year. What varies is whether your system is set up to send a claim that matches all three.

Audit the gender edit once and the male-patient rejections stop for good. Keep the ICD-10 pairing specific and the LCD check current, and most medical necessity denials go with them. The residual risk sits in panel bundling, which is why the quarterly NCCI check is worth putting in the calendar.

Book a demo to see how Pabau runs STI panel billing, from the eligibility check through to remittance posting.

Continue your research

Need to understand the full STI billing workflow? What is medical billing walks through the revenue cycle from order entry to payment posting.

Submitting claims electronically and want fewer rejections? Claim.MD clearinghouse guide covers how the clearinghouse validation layer catches errors before they reach the payer.

Getting denial codes back on NAAT claims? Denial codes in medical billing explains the most common CARC reason codes and how to work them.

Frequently asked questions